Drugmaker agrees to $4 million Medicare settlement
Somerset Lifesciences resolved allegations that Medicare paid for generic olopatadine after the corresponding brand-name eye drop moved over the counter.
Settlement concerns an eye-drop label
Somerset Lifesciences Inc. agreed to pay $4 million to resolve federal claims that Medicare Part D paid for the company’s generic olopatadine eye drops after the corresponding brand-name product became available without a prescription.
The brand-name Pataday Twice Daily Relief switched from prescription-only to over-the-counter sale in February 2020. Federal officials said the generic product’s label was required to mirror that change, but Somerset continued selling it with a prescription-only label.
Because Medicare Part D generally does not cover drugs available to retail customers over the counter, the government alleged that the unchanged label caused Medicare to pay claims that were not eligible for coverage.
The resolution does not establish every allegation at trial
The Justice Department described the matter as a common-law resolution based on unjust enrichment. Its announcement states that, except for admissions contained in the settlement agreement, the resolved claims remain allegations and there has been no determination of liability.
That distinction matters. A civil settlement can recover money and end a dispute without a court deciding every factual and legal issue after trial.
The case focuses on payment eligibility and product labeling, not on a new finding that olopatadine is unsafe or ineffective. Patients should not stop or change treatment based solely on the settlement announcement.
Prescription status affects federal payment
A prescription-to-OTC switch changes how a product is sold and often changes how insurance treats it. Medicare drug plans cover formularies of eligible prescription products; ordinary over-the-counter medicines are generally outside that benefit even when a clinician recommends them.
Generic labeling normally follows the reference brand so that directions, warnings and legal status remain aligned. If a generic keeps an obsolete prescription designation, pharmacy claims systems may process it differently from the over-the-counter brand.
The settlement is directed at the manufacturer and Medicare payments. It does not create an automatic refund process for every beneficiary who bought olopatadine, and the public announcement does not say patients must return products.
Beneficiaries with coverage questions should consult their Part D plan or Medicare rather than infer coverage from a store shelf or an old prescription. Clinicians and pharmacists remain the appropriate sources for medical advice. The broader compliance lesson is that manufacturers must update labels and billing pathways when a reference drug’s regulatory status changes, because administrative details can determine whether federal programs pay a claim.
Olopatadine is used for eye-allergy symptoms, but prescription history does not guarantee current Part D coverage. Plans and pharmacies may process products differently after an over-the-counter switch. Patients should ask about price, formulary status and alternatives before purchase rather than assuming the settlement changes an individual claim. Coverage questions remain entirely separate from treatment decisions.